Compare SATS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATS | NBIX |
|---|---|---|
| Founded | 2007 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 15.2B |
| IPO Year | 2007 | 1996 |
| Metric | SATS | NBIX |
|---|---|---|
| Price | $119.92 | $135.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $127.00 | ★ $177.14 |
| AVG Volume (30 Days) | ★ 5.0M | 1.1M |
| Earning Date | 02-26-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | N/A | ★ 4.19 |
| Revenue | ★ $15,175,913,000.00 | $2,682,700,000.00 |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | N/A | $18.47 |
| P/E Ratio | ★ N/A | $32.34 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $14.90 | $84.23 |
| 52 Week High | $119.80 | $160.18 |
| Indicator | SATS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 75.08 | 35.92 |
| Support Level | $107.59 | $134.20 |
| Resistance Level | $117.15 | $142.16 |
| Average True Range (ATR) | 4.60 | 3.07 |
| MACD | 0.04 | -1.08 |
| Stochastic Oscillator | 94.33 | 9.84 |
Satellite television provides the bulk of EchoStar's revenue. The firm serves about 5 million US satellite customers, about 10% of the traditional television market. It also serves 2 million customers under the Sling brand. EchoStar has also amassed an extensive portfolio of spectrum licenses and is building a nationwide wireless network. It acquired Sprint's prepaid business, serving approximately 7 million customers, primarily under the Boost brand. The firm has agreed to sell a portion of its wireless licenses to AT&T and will rely heavily on the AT&T network to serve customers. EchoStar's legacy businesses provide satellite telecom services and equipment to businesses and consumers, including about 800,000 internet customers.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.